



Patient ID 321	Patient Name TESTREFLABONESTTX, IMPLEMENTATION LABELS	Birth Date 1968-02-19	Sex M	Age 55
Order Number X100447641	Client Order Number X100447641	Ordering Physician 123	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 20 Nov 2023 11:00		

Infliximab QN with Antibodies, S

Infliximab, S

Interpretation

See the INXAB Interpretation for the final infliximab panel interpretation.

1 SDL

Infliximab, S

SDL

7.7 mcg/mL

REFERENCE VALUE

Limit of Quantitation = 1.0 mcg/mL

Infliximab Ab, S

INXAB Interpretation

Absence of detectable antibody-to-infliximab (ATI).

At this concentration of infliximab (IFX), a low-titer ATI (50–499 U/mL) cannot be completely excluded. However, the presence of a high-titer ATI (≥ 500 U/mL) is unlikely.

If clinical suspicion for a low-titer ATI is high, suggest submission of a new sample obtained at trough.

This test has demonstrated drug tolerance of up to 100 mcg/mL IFX for ATI ≥ 500 U/mL and up to 10 mcg/mL IFX for ATI < 500 U/mL.

1 SDL

Infliximab Ab, S

SDL

<20.0 U/mL

Reference Value
<50.0

Received: 20 Nov 2023 15:11

Reported: 21 Nov 2023 09:01

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592